We are a specialist pharmaceutical technology company developing and licensing solutions to add value to off patent and soon to be off patent drugs. Our technology portfolio includes delivery systems for liquid suspensions, solid state suspensions (soft chews) and superior chewable tablets, as well as our proprietary technologies OxpZero™ which allows for complete taste masking and OxpTarget™ which allows for precise drug delivery.
Oxford Pharmascience partners with London University on drug delivery deal
Oxford Pharmascience (LON:OXP) announced this morning that it has signed a deal with the University of London’s School of Pharmacy, giving the firm the option to license and research an advanced colonic drug delivery technology.
Oxford Pharmascience is already a specialist in various forms of drug delivery technology, but 18-month option will give it the opportunity to explore a whole new area of drug delivery. The platform technology, developed by the London School of Pharmacy’s Abdul Basit, provides for superior controlled delivery of drugs to the colon.
Targeting of drugs to the colon can help achieve localised therapy for such health problems as irritable bowel syndrome, constipation, diarrhoea, infection and carcinoma. But the colon can also be targeted as a way of getting drugs into the body that are designed to tackle health issues away from the bowel.
Oxford Pharmascience said that an international patent application for the technology was filed in 2007, with a priority claim to an earlier British case filed in 2006 that is now entering the national and regional phase.
"Accessing cutting edge technology from a strong academic partner such as the London School of Pharmacy gives Oxford Pharmascience significant capability to innovate and extend the lifecycle of off-patent and soon to be off-patent drugs," said Marcelo Bravo, Oxford Pharmascience’s chief technology officer.
"The superior colon targeting and drug release profile achieved by London School of Pharmacy’s drug delivery technology will enable us to develop a next generation application for a major drug category across markets worldwide.”